Boston Scientific lowered its 2026 earnings outlook and forecast a fourth-quarter sales decline after an August cyberattack disrupted global operations.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.